Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE

Chronic Lymphocytic Leukemia 144 videos

of 14

144 videos

Chronic Lymphocytic Leukemia

Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE

9:28
Module 4: Emerging BTK Inhibitors_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE

12:02
Module 2: Acalabrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MSCE

8:16
Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE

7:59
Module 5: Experts Debate Optimal Selection and Sequencing Strategies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE

21:45
Susan O’Brien, MD; University of California Irvine; #DDHO2022

20:24
Recently presented data and optimal therapeutic approaches in relapsed/refractory CLL_Jennifer Brown, MD, PhD; #BeyondASCO

13:52
Practical issues in CLL care: oral adherence, MRD testing, and managing treatment-related adverse events_Nicole Lamanna, MD; #BeyondASCO

12:51
Module 3_Treatment Strategies in the Relapsed Refractory Setting_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD

11:17
Module 4_Practical Issues in CLL Care_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD

10:33
Module 1_Introduction and Drivers of Treatment Decisions_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD

12:12
Next Page

of 14

ABOUT

Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.

The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.

CONNECT

support@bioascend.com

(888) 476-9129

980 North Michigan Avenue, Suite 1400, Chicago, IL 60611

Terms and Conditions | Privacy Policy

Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE

Module 4: Emerging BTK Inhibitors_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE

Module 2: Acalabrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MSCE

Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE

Module 5: Experts Debate Optimal Selection and Sequencing Strategies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE

Susan O’Brien, MD; University of California Irvine; #DDHO2022

Recently presented data and optimal therapeutic approaches in relapsed/refractory CLL_Jennifer Brown, MD, PhD; #BeyondASCO

Practical issues in CLL care: oral adherence, MRD testing, and managing treatment-related adverse events_Nicole Lamanna, MD; #BeyondASCO

Module 3_Treatment Strategies in the Relapsed Refractory Setting_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD

Module 4_Practical Issues in CLL Care_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD

Module 1_Introduction and Drivers of Treatment Decisions_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD

Share this video

Embed